Phio Pharmaceuticals Corp. Company profile
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp. is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. The Company has developed a product platform based on its INTASYL technology that allows selective non-genetically modified programming of adoptive cell therapy (ACT) cells and of the tumor micro-environment (TME), resulting in reduced immune inhibition and in improved immunotherapy. Its lead product candidate, PH-762, is an INTASYL compound that targets the checkpoint protein PD-1, which acts as a type of switch that prevents T cells from attacking certain cells, such as cancer cells, in the body. Its second product candidate, PH-894, is an INTASYL compound that targets BRD4, which is a regulator of gene expression impacting cell differentiation. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Phio Pharmaceuticals Corp revenues was not reported. Net loss increased 55% to $9.8M. Higher net loss reflects Research & Development Expenses - Balanc increase from $3.2M to $7M (expense), Labor & Related Expenses in SGA increase from $93K to $262K (expense), Stock-based Compensation in R&D increase from $17K to $80K (expense).
Equity composition
Common stock $.0001 Par, 1500M shares auth., 100,439,841 issd. Insider own 52.94%. 07/13, 1-for-30 reverse stock split. 04/16, 1-for-10 reverse stock split.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)